Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Receives $15.33 Consensus Target Price from Analysts

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have been assigned a consensus rating of “Buy” from the five analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $15.3333.

Several research firms have recently commented on RADX. Wall Street Zen lowered shares of Radiopharm Theranostics to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, January 22nd. Finally, B. Riley Financial restated a “buy” rating and issued a $16.00 price target (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of hedge funds have recently bought and sold shares of RADX. PNC Financial Services Group Inc. purchased a new position in shares of Radiopharm Theranostics in the 2nd quarter valued at about $37,000. Marex Group plc acquired a new stake in Radiopharm Theranostics in the fourth quarter valued at approximately $54,000. Finally, Jane Street Group LLC purchased a new position in Radiopharm Theranostics in the fourth quarter worth approximately $76,000.

Radiopharm Theranostics Stock Performance

Shares of Radiopharm Theranostics stock opened at $4.98 on Wednesday. The business has a 50-day moving average of $5.22 and a 200 day moving average of $5.39. Radiopharm Theranostics has a 12 month low of $3.50 and a 12 month high of $16.25.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.